Board of Directors
Chairman of the Board. Johan Reinsli was elected Chairmain of the Board in March 2008. He has been a board member in Navamedic since March 2007. Mr Reinsli is a graduate from Handelsakademiet, Oslo, Norway and has broad international management experience from the banking and finance sector. Previous executive positions include EVP at DnB NOR Kort, Head of Northern Europe at Europay International SA and CEO at Europrocessing International ASA, a company founded by Mr. Reinsli and colleagues. During his career Mr. Reinsli has been completing M&A activities in a number of EU and neighbouring countries. Mr Reinsli has broad international background from various board assignements, and currently works as an independent advisor and board member. Mr Reinsli holds indirectly 244,400 shares in the Company.
was elected Director of Navamedic in May 2013. Wenche Rolfsen holds a PhD title in pharmacology and has over 30 years' experience of the pharmaceutical industry. She has had leading positions at Pharmacia in the field of research and development, and was CEO of Quintiles Scandinavia AB. She holds numerous board positions - Chairman of the Board of Index Pharmaceutical AB, Vice Chairman of Moberg Derma AB (listed at NASDAQ Stockholm), board member of Industrifonden, Swedish Match AB (listed at NASDAQ Stockholm), APL AB, TFS AB and Sarsia Seed AS.
was elected Director of Navamedic in March 2008. Mr Stenstadvold holds a MSc Political Science from the University of Oslo. Mr Stenstadvold has long experience from different positions in Orkla, i.e responsible for Orkla Group's staff and Orkla Group's chemical area. Mr Stenstadvold has been Chairman of Bærum Municipality and Under Secretary at the Ministry of Government Administration. Mr Stenstadvold has broad experience as Board Member, from among others Storebrand ASA, Oslo Stock Exchange and the Resource Council of Norway. Mr Stenstadvold holds indirectly 24,000 and directly 10,000 shares in the Company.
was elected Director of Navamedic in March 2008. Ms Strømme holds a Ph.D in genetic and neuroscience from Oxford University in UK and has studied at McGill University in Canada. Ms Strømme has experience from investment banking with focus on Life Science from Morgan Stanley and Altium Capitals in London. Ms Strømme holds indirectly 80,000 shares in the Company.
Svein Erik Nicolaysen
was elected Director of Navamedic in August 2009. Mr Nicolaysen currently holds the position as CEO of the investment company Intersys Norge AS, a part of the group that is the largest shareholders in Navamedic ASA. He is an authorised accountant with accounting practice from Arthur Andersen and Vesterålen-Revisjon AS. From 1998 through 2008, Mr. Nicolaysen was the CEO of the company Vesterålen Naturprodukter AS and Nordic Sales Group AS, companies specialising in direct sales and marketing of health care products such as Omega 3 concentrates. After these companies were sold to Ferrosan AS (DK), Mr Nicolaysen was a member of the Management Board in Ferrosan AS until the end of 2008. Mr Nicolaysen holds 44.000 shares in the Company.